Heller SR, et al. - In people with type 2 diabetes (T2D), researchers examined the safety of insulin degludec (degludec) relative to age and risk of hypoglycemia post hoc. Participants in this crossover study with T2D who were at risk of hypoglycemia were randomized to double-blind treatment with degludec or insulin glargine 100 units/mL (glargine U100) ± oral antidiabetic drugs and then crossed over to the other treatment after 32 weeks. There were no significant differences in reduction of HbA1c in individuals ≤65 or >65 years. The authors concluded that degludec treatment was safe and effective with lower hypoglycemia frequency vs glargine U100 in both younger and older people (>65 years) with T2D.